Flash Finance

Dr Lalchandani Labs Ltd541299Corporate

Healthcare Service Provider Latest results: Mar 2026 13 quarters of data
₹7.84
MCap ₹7 Cr · P/E 96.8
Dr Lalchandani Labs Ltd — Stock analysis & AI research Dr Lalchandani Labs Ltd — Live exchange announcements
AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.
₹2 Cr
Sales · Mar 2026
-8.6% YoY
₹0 Cr
Operating Profit · Mar 2026
-74.5% YoY
6.1%
OPM % · Mar 2026
-72.1% YoY
₹-0 Cr
Net Profit · Mar 2026
-148.1% YoY
₹-0.15
EPS · Mar 2026
-148.4% YoY

📝 Dr Lalchandani Labs Ltd — results explained

Quarter ended March 2026 (Q4 FY26)

Dr Lalchandani Labs Ltd reported revenue of ₹2 crore for the quarter ended March 2026 (Q4 FY26), down 8.6% from ₹2 crore in the same quarter last year.

The company reported a net loss of ₹0 crore, against a net profit of ₹0 crore in the same quarter last year. Earnings per share (EPS) came in at ₹-0.15.

Operating profit stood at ₹0 crore — an operating margin (OPM) of 6.1%, compared with 21.9% in the year-ago quarter.

Full year and trailing twelve months

On a trailing-twelve-month (TTM) basis, revenue stands at ₹4 crore with a net profit of ₹0 crore.

Valuation snapshot

At the current price of ₹7.84, 541299 has a market capitalisation of ₹7 crore and a trailing P/E of about 96.8.

Within the Healthcare Service Provider industry, it is the 19th-largest of the 20 companies we track by market value.

Shareholding pattern

As of Mar 2026, promoters held 32.90%, public shareholders 67.10% of Dr Lalchandani Labs Ltd.

Promoter holding rose from 31.15% to 32.90% over the latest period.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close
Valuation
Market Cap ?
₹7 Cr
Current Price ?
₹7.8
P/E ?
96.77above ind
Industry P/E ?
22.50
P/B ?
0.48
P/S ?
1.62
P/FCF ?
-6.21
Enterprise Value ?
₹9 Cr
EV/EBITDA ?
22.65
PEG ?
3.58
Earnings Yield ?
-2.0%
Dividend Yield ?
0.00%
Profitability & Returns
Sales (TTM) ?
₹4 Cr
OPM ?
9.3%
Profit after tax (TTM) ?
₹0 Cr
EPS (TTM) ?
₹0.08
ROCE ?
0.8%
ROE ?
0.5%
ROA ?
0.4%
Growth
Sales — latest qtr ?
₹2 Cr
PAT — latest qtr ?
₹-0 Cr
YoY qtr sales growth ?
-8.6%
YoY qtr profit growth ?
-148.1%
Sales growth (3y) ?
-6%
Sales growth (5y) ?
-16%
Profit growth (3y) ?
27%
Profit growth (5y) ?
-43%
Financial Health
Debt ?
₹2 Cr
Debt to Equity ?
0.15
Interest Coverage ?
N/A
Current Ratio ?
N/A
Ownership
Promoter holding ?
32.90%
Change in promoter holding ?
-24.28%
Pledged percentage ?
N/A
Market
Return 3 months ?
-9.6%
Return 6 months ?
-49.7%

🗓️ Quarterly results (13 quarters · ₹ Cr)

same fiscal quarter as Mar bestweakest per row · for costs (interest, NPAs) low is best
Metric Mar 2020Sep 2020Mar 2021Sep 2021Mar 2022Sep 2022Mar 2023Sep 2023Mar 2024Sep 2024Mar 2025Sep 2025Mar 2026 YoY % QoQ %
Sales 3378323322222 -8.6% —
Operating Profit 11220-00011100 -74.5% —
Other Income 0000000000000 — —
Interest 0000001000000 -66.7% —
Depreciation 0000000000000 +3.6% —
Profit Before Tax 0011-0-1-1-01000-0 -185.0% —
Net Profit 0011-0-1-1-01000-0 -148.1% —
EPS 0.050.260.911.23-0.15-1.11-0.68-0.100.820.170.310.23-0.15 -148.4% —
OPM % 17.6% 21.0% 23.6% 24.3% 13.8% -7.9% 9.4% 12.8% 50.0% 25.4% 21.9% 12.7% 6.1% -72.1% —

📆 Annual results (₹ Cr, FY = Apr–Mar)

Annual rollup not yet available We need at least 3 quarters of a fiscal year to compute annual figures. This symbol does not yet have a complete fiscal year in our database.

🏛️ Balance Sheet (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Equity Capital 4.334.334.338.64 +99.5%
Reserves 4.595.215.625.50 -2.1%
Borrowings 6.403.484.072.06 -49.4%
Other Liabilities 2.401.971.721.40 -18.6%
Total Liabilities 17.7214.9915.7417.60 +11.8%
Fixed Assets 5.393.993.513.27 -6.8%
CWIP 0.000.000.000.00 —
Investments 0.240.410.270.27 +0.0%
Other Assets 12.0910.5911.9614.06 +17.6%
Total Assets 17.7214.9915.7417.60 +11.8%

💧 Cash Flow (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Cash from Operating Activity 0.00-0.220.37-0.76 -305.4%
Cash from Investing Activity -0.201.000.06-0.51 -950.0%
Cash from Financing Activity -0.23-1.590.582.12 +265.5%
Net Cash Flow -0.43-0.811.010.84 -16.8%
Free Cash Flow -0.300.740.30-1.09 -463.3%
CFO/OP 0%-100%40%-110% -375.0%

➗ Ratios (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Debtor Days 359.93356.65431.44532.26 +23.4%
Inventory Days 458.51255.15490.47306.69 -37.5%
Days Payable 404.21217.94365.00110.15 -69.8%
Cash Conversion Cycle 414.23393.86556.91728.79 +30.9%
Working Capital Days 188.29163.91156.66460.82 +194.2%
ROCE % -3.68%-2.68%2.81%0.79% -71.9%

👥 Shareholding (latest 4 periods)

Metric Sep 2024Mar 2025Sep 2025Mar 2026 % Chg
Promoters 57.18%48.32%31.15%32.90% +5.6%
Public 42.82%51.68%68.84%67.10% -2.5%
No. of Shareholders 181246206233 +13.1%

⚖️ Peer comparison

Industry: Healthcare Service Provider · 20 companies · full page →
# Company CMP MCap (Cr) P/E Sales TTM NP TTM OPM% NPM% Sales YoY% NP YoY% Qtr Rev Δ% Qtr NP Δ%
1 NEPHROPLUS Nephrocare Health ₹673.00 6,768 78.9 1,054 85 22.8% 8.1% — — 23.6% 33.2%
2 532067 3B BlackBio ₹1,205.90 1,166 18.8 153 56 34.9% 36.7% 47.1% 25.7% 50.7% -29.0%
3 514330 One Global ₹139.00 1,043 3.7 513 74 19.1% 14.5% 311.6% 288.9% 16.8% 43.0%
4 HEALTHX Health X ₹306.95 976 — 0 -1 -390.4% -376.2% — — -20.0% -367.5%
5 526546 Choksi Laboratories ₹61.93 146 19.9 47 2 26.8% 4.6% 10.1% 28.8% 7.5% 49.3%
6 540788 Aspira Pathlab ₹31.00 107 — 26 -0 3.8% -1.7% 13.5% -97.1% 17.5% -108.5%
7 530897 NG Industries ₹165.30 39 28.7 17 2 11.1% 11.4% -0.9% -77.7% 13.8% 104.3%
8 524602 Bandaram Pharma ₹30.99 33 162.8 79 1 4.8% 1.5% 70.2% -46.9% 195.7% 3322.0%
9 524548 Sharma East ₹50.09 32 13.9 37 1 9.6% 3.2% 20.3% 0.0% 13.7% -18.7%
10 542248 Deccan Health ₹35.53 30 34.8 82 3 6.4% 3.1% 9.1% 115.7% -0.3% 21.3%
11 539267 Samsrita Labs ₹17.13 28 — — — — — — — — —
12 523489 Chennai Meenakshi ₹34.47 28 — 37 -0 1.5% -1.1% 6.4% 16.1% -0.7% 100.4%
13 539428 Tejnaksh Healthcare ₹23.46 27 38.5 11 1 26.5% 11.3% -16.3% -47.5% 0.5% 24.1%
14 526139 Transgene Biotek ₹9.56 21 — 0 -2 -223.0% -766.2% -25.9% -146.3% 20.0% 9.5%
15 516110 Family Care ₹7.44 11 — 0 -8 -1321.3% -3505.7% -97.3% 80.3% 150.0% 39.5%
16 534422 Looks Health ₹5.73 10 177.4 0 0 41.2% 7.5% -2.6% 0.0% 75.7% —
17 531043 Dhanvantri Jeevan ₹19.95 10 16.1 28 1 3.2% 1.8% 14.2% -23.5% 41.6% 200.0%
18 526504 Dolphin Medical ₹1.85 10 5.2 1 0 13.0% 7.4% -2.6% 333.3% 21.2% -40.7%
19 541299 Dr Lalchandani ₹27.60 7 345.0 4 0 9.3% 1.7% — — -8.6% -148.1%
20 526187 Ashram Online.Com ₹6.29 7 — 1 -0 -74.9% -20.3% 33.3% -71.4% 31.6% 40.2%
❓ Frequently asked questions
What was Dr Lalchandani Labs Ltd's revenue in Q4 FY26?
Dr Lalchandani Labs Ltd reported revenue of ₹2 crore for the quarter ended March 2026 (Q4 FY26), down 8.6% from ₹2 crore in the same quarter last year.
What was Dr Lalchandani Labs Ltd's net profit in Q4 FY26?
The company reported a net loss of ₹0 crore, against a net profit of ₹0 crore in the same quarter last year. Earnings per share (EPS) came in at ₹-0.15.
What is 541299's market capitalisation and P/E ratio?
At the current price of ₹7.84, 541299 has a market capitalisation of ₹7 crore and a trailing P/E of about 96.8.
Who owns Dr Lalchandani Labs Ltd? (shareholding pattern)
As of Mar 2026, promoters held 32.90%, public shareholders 67.10% of Dr Lalchandani Labs Ltd.
TTM ends 2026-03-31. Amounts are ₹ crore unless stated otherwise. Figures are extracted by AI from public quarterly filings; gaps are filled from public market data. Live price refreshed about twice a day from exchange data. Educational information only — not financial advice.
⚠️ How this site is made: Market data pages are computed automatically from NSE/BSE publications and company filings; news articles and announcement analyses are written with AI assistance, with a human in the loop: our editors review what the AI produces. Both can contain errors. Verify with the original sources before any investment decision. Not investment advice; Flash Finance is not SEBI-registered. How we use AI